|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||309.362 g/mol g·mol−1|
|3D model (JSmol)|
Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker. It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication. Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned, and the drug was ultimately never marketed.
- Feigin V (June 2002). "Irampanel Boehringer Ingelheim". Curr Opin Investig Drugs. 3 (6): 908–10. PMID 12137411.
- Wang KK, Larner SF, Robinson G, Hayes RL (December 2006). "Neuroprotection targets after traumatic brain injury". Curr. Opin. Neurol. 19 (6): 514–9. doi:10.1097/WCO.0b013e3280102b10. PMID 17102687.
- Arunabha Ray; Kavita Gulati (1 January 2007). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7.
- Weiser T (April 2005). "AMPA receptor antagonists for the treatment of stroke". Curr Drug Targets CNS Neurol Disord. 4 (2): 153–9. PMID 15857300.
|This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.|